Silvia Geraci

Chiesi (Italy) — Italy

Medicine · Health Sciences

8h-index321citations28works1.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lysosomal Storage Disorders Research(9), Asthma and respiratory diseases(4), Trypanosoma species research and implications(4), Renal Transplantation Outcomes and Treatments(3), Sexual Differentiation and Disorders(3)

Publications28 total

Evaluating the impact of changing inhaler color on perception of symptoms and disease burden in patients with asthma: the FEEL study
Journal of Asthma·2025· 1 citedOpen Access
EPH139 A Retrospective Cohort Study of Pediatric Patients Undergoing Percutaneous Vascular Procedures
Value in Health·2023Open Access
Prolonged-Release Once-Daily Formulation of Tacrolimus Versus Standard-of-Care Tacrolimus in de novo Kidney Transplant Patients Across Europe
Transplant International·2022· 14 citedOpen Access
Peregrine Horden – Nicholas Purcell, “The Boundless Sea”
Storicamente·2022Open Access
Use of the Bruininks-Oseretsky test of motor proficiency (BOT-2) to assess efficacy of velmanase alfa as enzyme therapy for alpha-mannosidosis
Molecular Genetics and Metabolism Reports·2020· 13 citedOpen Access
Effect of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor (PDE4i) on markers of inflammation in COPD patients
2019
Effect of the inhaled PDE4 inhibitor CHF6001 on biomarkers of inflammation in COPD
Respiratory Research·2019· 75 citedOpen Access
Effects of the Novel Inhaled Phosphodiesterase-4 (PDE4) Inhibitor CHF6001 in Targeting Markers of Inflammation in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis
2019
Pharmacokinetics of Prolonged-Release Once-Daily Formulations of Tacrolimus in De Novo Kidney Transplant Recipients: A Randomized, Parallel-Group, Open-Label, Multicenter Study
Advances in Therapy·2018· 34 citedOpen Access
Efficacy and safety of Velmanase alfa in the treatment of patients with alpha‐mannosidosis: results from the core and extension phase analysis of a phase III multicentre, double‐blind, randomised, placebo‐controlled trial
Journal of Inherited Metabolic Disease·2018· 59 citedOpen Access
Comprehensive long‐term efficacy and safety of recombinant human alpha‐mannosidase (velmanase alfa) treatment in patients with alpha‐mannosidosis
Journal of Inherited Metabolic Disease·2018· 55 citedOpen Access
Enzyme replacement therapy with velmanase alfa (human recombinant alpha-mannosidase): Novel global treatment response model and outcomes in patients with alpha-mannosidosis
Molecular Genetics and Metabolism·2018· 48 citedOpen Access
Gender, mutations and residual enzymatic activity: Investigation of predictive factors of alpha-mannosidosis phenotypic presentation and of response to velmanase alfa long term enzyme replacement therapy
Molecular Genetics and Metabolism·2018
Global treatment response analysis of velmanase alfa long term enzyme replacement therapy for alpha-mannosidosis shows treatment benefit across ages
Molecular Genetics and Metabolism·2018
Global treatment responder analysis demonstrates clinically relevant effect of velmanase alfa long term enzyme replacement therapy for alpha mannosidosis, in a phase III randomized placebo controlled trial
Molecular Genetics and Metabolism·2018
Health Related Quality of Life, Disability, and Pain in Alpha Mannosidosis
Journal of Inborn Errors of Metabolism and Screening·2018· 8 citedOpen Access
Pharmacokinetics of Prolonged-Release Once-Daily Formulations of Tacrolimus in De-novo Kidney Transplant Recipients: A Randomized, Parallel Group, Open Label, Multicenter Study
HAL (Le Centre pour la Communication Scientifique Directe)·2018Open Access
Long-term enzyme replacement therapy with velmanase alfa (human recombinant alpha-mannosidase) slows disease progression in adult patients suffering from alpha-mannosidosis
Molecular Genetics and Metabolism·2017· 4 cited
Improvement in pulmonary function and serum immunoglobulin G in long-term enzyme replacement therapy with velmanase alfa(human recombinant alpha-mannosidase) in alpha-mannosidosis patients
Molecular Genetics and Metabolism·2017
Long-term enzyme replacement therapy with velmanase alfa (human recombinant alpha-mannosidase) improves mobility in alpha-mannosidosis patients
Molecular Genetics and Metabolism·2017· 1 cited
page 1 of 2Next →

Frequent Co-authors

Line Borgwardt(12), Nathalie Guffon(12), Diego Ardigò(12), Federica Cattaneo(12), Allan M. Lund(12), Mercedes Gil‐Campos(11), Anna Tylki‐Szymańska(11), Yasmina Amraoui(10), Linda De Meırleır(9), Simon Jones(9), Nicole Muschol(9), Frits A. Wijburg(7), Bénédicte Héron(6), J. Fogh(6), Paul Harmatz(6), Mirco Govoni(5), Christine í Dali(5), Philippe Dolhem(5), Dave Singh(4), Dawn Phillips(4)